HSA ~25.19GLP-1 & Dual GIP/GLP-1 Receptor Agonists: Nutrient Depletions, Dosing Rules & HSA/FSA Guide
Caloric restriction and slowed gastric emptying from GLP-1 receptor agonism accelerate disproportionate loss of fat-free skeletal muscle mass (25–40% of weight lost without resistance + protein co-intervention), reduce micronutrient intake, and increase constipation and hypovolemic electrolyte shifts.
Oral medications or capsules may show delayed absorption on GLP-1 therapy; maintain 64+ oz hydration daily with buffered electrolytes and pair protein/creatine with progressive resistance exercise 2–3x/week. Disclose all supplements to prescriber if persistent nausea or biliary symptoms arise.
Documented Nutrient Depletions & Support Needs
Supports phosphocreatine ATP regeneration and slows proteolysis during negative energy balance alongside resistance training.
Mitigates GLP-1 delayed gastric emptying, satiety bloating, and slow colonic transit.
Rapid weight reduction decreases mechanical skeletal loading and oral B-vitamin / mineral density.
Lab Targets to Review
- CMP / eGFR (hydration & creatinine stability)
- Serum 25(OH) Vitamin D (40–60 ng/mL)
- Serum Vitamin B12 + Ferritin
- DEXA Body Composition (Appendicular Lean Mass Index)
Matched Physical Formulations & Supplies (8)
Quality-verified formulations and home monitoring equipment aligned to GLP-1 (Ozempic / Mounjaro / Zepbound).
HSA ~25.19
HSA ~37.09Clinical Multi-Strain Probiotic (50 Billion CFU)
HSA ~33.59Clinical Electrolyte & Cellular Hydration Complex
HSA ~29.39Menopause & Perimenopause Vasomotor Support
HSA ~34.29Women's Health Foundational Essentials
HSA ~29.39Digestive Enzymes, Betaine HCl & Gallbladder Bile Support
HSA ~46.19Gut Motility & Prokinetic Support (Standardized Ginger + Artichoke + PHGG Fiber)
HSA ~15.39Bone Support & Microcrystalline Hydroxyapatite Complex (MCHC Calcium + D3 + K2 MK-7 + Magnesium)
Frequently Asked Questions — GLP-1 (Ozempic / Mounjaro / Zepbound) & Supplementation
What nutrients or physical functions are impacted by GLP-1 (Ozempic / Mounjaro / Zepbound)?+
Caloric restriction and slowed gastric emptying from GLP-1 receptor agonism accelerate disproportionate loss of fat-free skeletal muscle mass (25–40% of weight lost without resistance + protein co-intervention), reduce micronutrient intake, and increase constipation and hypovolemic electrolyte shifts. Key replenishment or monitoring areas include Lean Muscle Preservation (Creatine Monohydrate + HMB) (Supports phosphocreatine ATP regeneration and slows proteolysis during negative energy balance alongside resistance training.); Soluble GI Motility Fiber & Digestive Enzymes (Mitigates GLP-1 delayed gastric emptying, satiety bloating, and slow colonic transit.); Bone Density & Micronutrient Buffer (D3+K2, Electrolytes, B12) (Rapid weight reduction decreases mechanical skeletal loading and oral B-vitamin / mineral density.)
What is the most important dosing separation or safety rule with GLP-1 (Ozempic / Mounjaro / Zepbound)?+
Oral medications or capsules may show delayed absorption on GLP-1 therapy; maintain 64+ oz hydration daily with buffered electrolytes and pair protein/creatine with progressive resistance exercise 2–3x/week. Disclose all supplements to prescriber if persistent nausea or biliary symptoms arise.
Which lab tests should I discuss with my prescriber while taking GLP-1 (Ozempic / Mounjaro / Zepbound)?+
Recommended monitoring targets to review with your physician or pharmacist include: CMP / eGFR (hydration & creatinine stability), Serum 25(OH) Vitamin D (40–60 ng/mL), Serum Vitamin B12 + Ferritin, DEXA Body Composition (Appendicular Lean Mass Index).
Are targeted supplements or recovery supplies for GLP-1 (Ozempic / Mounjaro / Zepbound) HSA and FSA eligible?+
GLP-1 lean muscle, bone-sparing, and GI motility formulations pair with obesity/prediabetes/type 2 diabetes ICD-10-CM diagnoses (E66.x, R73.03, E11.x) for ~30% pre-tax HSA/FSA savings. Eligible physical products save roughly 22% to 37% (~30% average) when purchased or reimbursed with pre-tax HSA/FSA dollars backed by IRS Section 213(d) documentation.
